Filing Flows › Companies › Bio-Rad Laboratories › Analysis traps
Bio-Rad Laboratories (BIO): analysis traps
Where its figures could mislead a reader, and what to check before taking them at face value · Data: Q3 2026, to Sep 30, 2026, filed Nov 4, 2026; rules v1.1
Bio-Rad Laboratories (BIO): 1 rule of 10 triggered on the filings to Sep 30, 2026: FCF growth = the business improved; 2 with insufficient data; 3 not applicable. Each is a question to verify, with the normal explanation that would produce the same figures.
Check these first
FCF growth = the business improved Triggered · severity high · confidence medium
Free cash flow rose $85M (+29%), from $290M to $375M, but working capital released $84M more cash than the year before and capital expenditure fell by $8M: more than the whole increase came from sources that need not repeat. Operating cash flow before working capital fell by $7M.
Innocent reading: An expansion programme finished, so capex fell back to maintenance levels for good.
Every rule
A01 FCF growth = the business improved Triggered severity high · confidence medium
Free cash flow rose $85M (+29%), from $290M to $375M, but working capital released $84M more cash than the year before and capital expenditure fell by $8M: more than the whole increase came from sources that need not repeat. Operating cash flow before working capital fell by $7M.
The figures and how they are read
| Fiscal year before | FY2024 |
| Fiscal year | FY2025 |
| Operating cash flow, year before | $455M |
| Operating cash flow | $532M |
| Capex, year before | $166M |
| Capex | $158M |
| Free cash flow, year before | $290M |
| Free cash flow | $375M |
| Change in FCF | $85M |
| Change in capex | −$8M |
| Working capital: change in its cash contribution | $84M |
| Of which: capex cut | $8M |
| Of which: working capital released | $84M |
| Share of the increase that need not repeat | +108.6% |
| Operating cash flow before working capital: change | -7300000.00 |
FCF = operating cash flow − cash capex; ΔFCF = ΔOCF − ΔCapEx; the working-capital part is the change in the cash-bridge items (receivables, inventory, payables, accruals), with the sign of the cash flow statement
Source: FY2025 (cash flow statement, fiscal year) · FY2024 (cash flow statement, fiscal year before)
What would explain it innocently
- An expansion programme finished, so capex fell back to maintenance levels for good
- Suppliers agreed longer payment terms in a contract
- Inventory was brought down after a glut and will stay down
What to look for in the filing
- Maintenance capex (what it costs to keep the assets working)
- Supplier payment terms and any supply-chain financing
- Management's capex guidance for next year
What would show the trap does not apply
- Next year's FCF holds or rises with capex back at its earlier level and working capital no longer releasing cash
- The 10-K's capex guidance and the segment capex show the cut is a completed programme, not deferral
- The working-capital release matches a disclosed change in terms or a divestiture, not stretched payables or a collection push
Look again: next filing.
A07 Stock compensation added back = no economic cost Not triggered confidence high
Stock compensation is 2.2% of revenue: small enough that adding it back changes little.
The figures and how they are read
| Fiscal year | FY2025 |
| Stock compensation | $58M |
| Revenue | $2.6B |
| SBC / revenue | +2.2% |
| Buybacks | $296M |
| Buybacks / SBC | 5.1 |
| Diluted shares, year before | 28.2M shares |
| Diluted shares | 27.3M shares |
| Diluted shares: change | -3.3% |
SBC / revenue from the cash flow statement's add-back; the diluted weighted share count year over year; buybacks from the financing section
Source: FY2025 (stock compensation, buybacks and the diluted share count, fiscal year)
B02 Receivables growing = future cash is certain Not triggered confidence medium
Receivables grew -9% against revenue 1% in Q3 2026; DSO 61 against a median of 63: collections are keeping pace with sales.
The figures and how they are read
| Quarter | Q3 2026 |
| Revenue, year over year | +0.5% |
| Receivables, year over year | -9.1% |
| Quarter before | Q2 2026 |
| Revenue y/y, quarter before | -0.1% |
| Receivables y/y, quarter before | -6.0% |
| Days sales outstanding | 60.6 |
| DSO, median of eight quarters | 63.0 |
| Receivables | $423M |
| Revenue | $656M |
receivables and revenue against the same quarter a year earlier; DSO = receivables / quarterly revenue × days, against the median of the eight quarters before
Source: Q3 2026 (receivables and revenue) · Q3 2025 (the same quarter a year earlier)
B08 Adjusted profit = economic profit Insufficient data
no reconciliation table read from the releases yet and fewer than three quarters with both an adjusted and a GAAP EPS
C02 Low net debt = no refinancing risk Not triggered confidence medium
$1M comes due within a year, 1533.4× covered by cash and investments of $1.7B plus $329M of free cash flow.
The figures and how they are read
| Cash and investments | $1.7B |
| Debt | $1.2B |
| Net debt | −$460M |
| Due within a year | $1M |
| Read from | the debt maturity table |
| Free cash flow, twelve months | $329M |
| Cash plus free cash flow | $2.0B |
| Coverage of what is due | 1533.4 |
| Due in the second year | $400M |
| Balance sheet date | 2026-09-30 |
due within a year from the maturity table (else the current portion of debt), against cash and investments plus free cash flow over the last twelve months (zero if negative); no credit lines assumed
Source: FY2025 (debt maturities, cash and investments)
D03 EPS growth = profit growth Not applicable
a loss in one of the quarters: EPS growth has no meaning
E02 Low P/E at a cyclical peak = undervalued Not triggered confidence medium
Net income of $1.0B is not at a cyclical high against the last eight years (median $760M, best $4.2B): the P/E of 10.1× is on a normal year.
The figures and how they are read
| market value | $10.3B |
| net income ttm | $1.0B |
| pe ttm | 10.10 |
| net income median fy | $760M |
| pe mid cycle | 13.50 |
| net income peak fy | $4.2B |
| years | FY2018 / 366.0; FY2019 / 1759.0; FY2020 / 3806.0; FY2021 / 4246.0; FY2022 / -3628.0; FY2023 / -637.0; FY2024 / -1844.0; FY2025 / 760.0 |
| down years in window | 2 |
P/E on the trailing twelve months' net income against the P/E on the median net income of the last eight fiscal years (a mid-cycle stand-in); 'at a peak' = this year's profit at or above 90% of the best year and at least 1.3× the median
Source: Q3 2026 (net income, trailing twelve months)
E07 A precise DCF value = the true value Insufficient data
no DCF in the valuation research for this company
J06 A bank's low P/E and high profit = safe Not applicable
not a bank
J08 A REIT's low net income = the dividend is unsafe Not applicable
not a REIT
What the statuses mean
Triggered: the filings show the pattern; read the normal explanations and the missing evidence before concluding anything. To review: one quarter or a weak signal; a reader's judgement, not a pattern. Not triggered: the pattern is absent on these figures. Insufficient data: the filings read so far do not hold what the rule needs; this is not a clean bill. Not applicable: the rule is not meant for this kind of company (a bank's working capital, a loss-making quarter's EPS growth). Out of date: the latest filing is more than fifteen months old.
Severity is what the pattern could mean for cash, value or solvency; confidence is how reliable the inputs and the reading are. The two are kept apart.
Record a view
A reader's judgement, grounds, what would change it and the next review; kept in the browser (needs JavaScript).
Every rule and the companies it triggers on → Bio-Rad Laboratories: cash flow → Earnings quality score →
Each rule reads the company's own filings by a fixed formula and says what would explain the same figures innocently. A triggered rule is a question to verify, not a finding of manipulation, and not a view on the stock. Missing data is shown as missing, never as clear. Not investment advice.